Contrasting Cencora (COR) & Its Competitors

Cencora (NYSE:COR) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its competitors? We will compare Cencora to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Cencora and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cencora	$321.33 billion	$1.55 billion	26.20
Cencora Competitors	$21.01 billion	$288.54 million	7.34

Cencora has higher revenue and earnings than its competitors. Cencora is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Dividends

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. Cencora pays out 17.8% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.4% and pay out 25.2% of their earnings in the form of a dividend. Cencora has increased its dividend for 15 consecutive years.

Insider and Institutional Ownership

97.5% of Cencora shares are held by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 0.4% of Cencora shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Cencora has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Cencora’s competitors have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Cencora and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cencora	0.79%	125.45%	4.18%
Cencora Competitors	-7.69%	-141.09%	-1.47%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cencora and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0	4	14	0	2.78
Cencora Competitors	1852	7707	13270	815	2.55

Cencora currently has a consensus target price of $368.38, indicating a potential upside of 4.44%. As a group, “Healthcare Providers & Services” companies have a potential upside of 11.97%. Given Cencora’s competitors higher possible upside, analysts plainly believe Cencora has less favorable growth aspects than its competitors.

Summary

Cencora beats its competitors on 10 of the 15 factors compared.

Cencora Company Profile

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.